

# Clinical trials of poly ADP-ribose polymerase (PARP) inhibitor for advanced breast cancer (metastatic) in BRCA-mutated

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 poly ADP-ribose polymerase (PARP) inhibitor

Trial	Treatments	Patients	Trials design and methods
<b>niraparib vs Physician s choice chemotherapy</b>			
<b>BRAVO</b> <i>ongoing</i> [NCT01905592] n=NA follow-up:	niraparib 3 oral capsules (100mg) once daily for 21 continuous days versus Physician's choice (Physician may select from 4 active comparators)	patients with advanced/metastatic breast cancer who have a BRCA gene change	
<b>olaparib vs Physician s choice chemotherapy</b>			
<b>OlympiAD</b> , 2017 [NCT02000622] n=205/97 follow-up: 14.5 months	Olaparib (Olaparib tablet 300mg bd po) versus Physician's choice chemotherapy (Capecitabine 2500 mg/m2 d1-14 q 21, or Vinorelbine 30 mg/m2 d1,8 q 21, or Eribulin 1.4 mg/m2 d1,8 q 21)	women with human epidermal growth factor 2 (HER2)negative metastatic breast cancer with a germline BRCA mutation	open label
<b>talazoparib vs Physician s choice chemotherapy</b>			
<b>EMBRACA</b> <i>ongoing</i> [NCT01945775] n=NA follow-up:	talazoparib oral capsules (1.0 mg) once daily for 21 continuous days versus Physician's-Choice (Capecitabine, Eribulin, Gemcitabine or Vinorelbine)	patients who have locally advanced and/or metastatic breast cancer with germline BRCA mutations	USA
<b>veliparib with carboplatin and caclitaxel vs Placebo with Carboplatin and Paclitaxel</b>			
<b>NCT02163694</b> <i>ongoing</i> [NCT02163694] n=NA follow-up:	Veliparib with Carboplatin and Paclitaxel (Veliparib on Day -2 through 5 of a 21-day cycle. In addition, carboplatin and paclitaxel will be administered on Day 1 of a 21-day cycle.) versus Placebo with Carboplatin and Paclitaxel (Placebo on Day -2 through 5 of a 21-day cycle. In addition, carboplatin and paclitaxel will be administered on Day 1 of a 21-day cycle.)	HER2-negative metastatic or locally advanced, unresectable, BRCA-associated breast cancer	

## References

BRAVO, :  
OlympiAD, 2017:

Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017 Jun 4;: [28578601] [10.1056/NEJMoa1706450](https://doi.org/10.1056/NEJMoa1706450)

**EMBRACA, :**

**NCT02163694, :**

## 2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.